SteadySkin — What’s new https://steadyskin.app/whats-new/ Verified SteadySkin treatment, research, program, and guide updates. Europe’s CHMP issued a positive opinion for Rinvoq (upadacitinib) in nonsegmental vitiligo. This is not an approval; the European Commission decision is pending. https://steadyskin.app/vitiligo/whats-coming/ https://steadyskin.app/vitiligo/whats-coming/#rinvoq-chmp-positive-opinion-2026-06 Fri, 26 Jun 2026 12:00:00 GMT vitiligo program-change Incyte reported that its Phase 3 povorcitinib vitiligo studies met their main goal and said future regulatory applications are planned. https://steadyskin.app/vitiligo/whats-coming/ https://steadyskin.app/vitiligo/whats-coming/#povorcitinib-phase-3-report-2026-04 Tue, 28 Apr 2026 12:00:00 GMT vitiligo research AbbVie reported FDA and EMA submissions for Rinvoq (upadacitinib) in nonsegmental vitiligo. It remains unapproved for vitiligo. https://steadyskin.app/vitiligo/whats-coming/ https://steadyskin.app/vitiligo/whats-coming/#rinvoq-submission-2026-02 Wed, 04 Feb 2026 12:00:00 GMT vitiligo program-change